284 related articles for article (PubMed ID: 33563487)
1. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.
Siedel JH; Ring KL; Hu W; Dood RL; Wang Y; Baggerly K; Darcy KM; Conrads TP; Gallagher S; Tshiaba P; Neff C; Timms KM; Mangala S; Westin SN; Broaddus R; Lopez-Berestein G; Lu KH; Coleman RL; Maxwell GL; Sood AK
Gynecol Oncol; 2021 Mar; 160(3):777-785. PubMed ID: 33563487
[TBL] [Abstract][Full Text] [Related]
2. Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.
de Jonge MM; Auguste A; van Wijk LM; Schouten PC; Meijers M; Ter Haar NT; Smit VTHBM; Nout RA; Glaire MA; Church DN; Vrieling H; Job B; Boursin Y; de Kroon CD; Rouleau E; Leary A; Vreeswijk MPG; Bosse T
Clin Cancer Res; 2019 Feb; 25(3):1087-1097. PubMed ID: 30413523
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
Lin DI; Fine A; Danziger NA; Huang RSP; Mata DA; Decker B; Killian JK; Ramkissoon SH; Lechpammer M; Janovitz T; Ross JS; Sokol ES; Elvin JA
Gynecol Oncol; 2022 Mar; 164(3):558-565. PubMed ID: 34998597
[TBL] [Abstract][Full Text] [Related]
4. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
5. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
6. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
[No Abstract] [Full Text] [Related]
7. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
9. Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P).
Zhu S; Zhao J; Nie L; Yin W; Zhang Y; Zhao F; Ni Y; Zhang X; Wang Z; Dai J; Liu Z; Chen J; Zeng Y; Wang Z; Sun G; Liang J; Zhao X; Zhu X; Tao R; Yang J; He B; Chen N; Shen P; Zeng H
BMC Med; 2022 Jul; 20(1):237. PubMed ID: 35864546
[TBL] [Abstract][Full Text] [Related]
10. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
[TBL] [Abstract][Full Text] [Related]
11. Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
Beinse G; Just PA; Le Frere Belda MA; Laurent-Puig P; Jacques S; Koual M; Garinet S; Leroy K; Delanoy N; Blons H; Gervais C; Durdux C; Chapron C; Goldwasser F; Terris B; Badoual C; Taly V; Bats AS; Borghese B; Alexandre J
Br J Cancer; 2022 Oct; 127(6):1123-1132. PubMed ID: 35752712
[TBL] [Abstract][Full Text] [Related]
12. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A
J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413
[TBL] [Abstract][Full Text] [Related]
13. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
[TBL] [Abstract][Full Text] [Related]
14. Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
Sztupinszki Z; Diossy M; Borcsok J; Prosz A; Cornelius N; Kjeldsen MK; Mirza MR; Szallasi Z
Clin Cancer Res; 2021 Oct; 27(20):5681-5687. PubMed ID: 34380641
[TBL] [Abstract][Full Text] [Related]
15. Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer.
Wu X; Wang Q; Liu P; Sun L; Wang Y
Front Genet; 2022; 13():1026871. PubMed ID: 36468004
[No Abstract] [Full Text] [Related]
16. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
17. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
How JA; Jazaeri AA; Fellman B; Daniels MS; Penn S; Solimeno C; Yuan Y; Schmeler K; Lanchbury JS; Timms K; Lu KH; Yates MS
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668244
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
[TBL] [Abstract][Full Text] [Related]
19. Biomarker Assessment of HR Deficiency, Tumor
Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
[TBL] [Abstract][Full Text] [Related]
20. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
